Charlotte Pawlyn, BA, MBBChir, MRCP, PhD, FRCPath, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, shares some insights into the Phase III Myeloma XIV (FiTNEss) trial (NCT03720041), which is evaluating whether the IMWG frailty score may be used to dose adapt induction therapy for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
